Evidence map›Paper›PMID 16222083›Full record

ReviewClinical reviews in allergy & immunology2005

IgE and FcepsilonRI regulation.

Donald MacGlashan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 34 citations in OpenAlex.

  1. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab.The Journal of allergy and clinical immunology · 2018
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. The Effector Function of Allergens.Frontiers in allergy · 2022
    Review
  7. Article
  8. Article
  9. Human FcR polymorphism and disease.Current topics in microbiology and immunology · 2014
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Donald MacGlashanJohns Hopkins Asthma and Allergy Center, Baltimore, MD, USA. dmacglas@jhmi.edu
Johns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high-affinity immunoglobulin (Ig)E receptor, FcepsilonRI, regulates the action of mast cells and basophils and therefore, regulates the expression of atopic disease. There have been several recent observations that demonstrate new behaviors for this receptor. The control of FcepsilonRI expression, control of cell function by FcepsilonRI, and expression of FcepsilonRI on other cell types are important new areas of understanding currently being explored.

Indexed as

AnimalsBasophilsDendritic CellsGene Expression RegulationHumansImmunoglobulin EMast CellsPolymorphism, GeneticProtein SubunitsReceptors, IgESignal TransductionImmunoglobulin EProtein SubunitsReceptors, IgE

Identifiers

PMID16222083
OpenAlexW2059616949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.